Fundraising Fox
/Companies
Sign in

Aquestive Therapeutics

NASDAQ: AQST

Warren, US · Delaware corporation · 150 employees on LinkedIn · 2 known investors

Find your way into Aquestive Therapeutics

617 people in our graph can introduce you to the Aquestive Therapeutics team.

Sign up to see every warm intro you have to Aquestive Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Aquestive Therapeutics team. We find them
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Aquestive Therapeutics develops and commercializes oral film drug formulations and other novel delivery systems for treatments in neurology, psychiatry, and emergency care, operating manufacturing facilities in Indiana that produce both licensed pharmaceutical products and proprietary candidates for regulated markets including the U.S., EU, and Australia.

Biotech

Founders & leadership

KJKeith J Kendall
Keith J KendallChief Executive Officer2014–2022Keith Kendall is Chief Executive Officer of Aquestive Therapeutics, where he brings extensive experience in business operations, strategy, and capital markets. He has held financial leadership roles including CFO and has served on public, private, and non-profit boards in the U.S. and U.K., with experience in mergers, acquisitions, and public offerings.
AM
A. Mark ShobelChief Operating Officer
TW
Theresa WoodSVP2006–2022
PB
Peter BoydVice President, Value Delivery
DBDaniel Barber
Daniel BarberChief Executive OfficerDaniel Barber is Chief Operating Officer at Aquestive Therapeutics, a pharmaceutical company developing oral film formulations and novel drug delivery systems. He has held leadership roles in pharmaceutical product development, corporate and business development, and operations.
JTJohn T Maxwell
John T MaxwellChief Financial Officer2017–2020He has held senior finance roles managing mergers and acquisitions, capital markets transactions including IPOs and debt recapitalizations, and operations in life sciences and healthcare sectors.
GB
Gregory BrownNamed on SEC filing
DB
Douglas BrattonNamed on SEC filing
JC
John CochranNamed on SEC filing
SC
Santo CostaNamed on SEC filing
JS
James S ScibettaNamed on SEC filing

Investors · 2

RTW Investments L.P.reportedNew York

How we know: a partner's Signal profile · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$9.1M disclosed across 1 round · 2018

▶$9.1MraisedMay 2018 · 15 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Gregory BrownDirector
  • Keith J KendallExecutive Officer, Director
  • A. Mark ShobelExecutive Officer, Director
  • Theresa WoodExecutive Officer
  • Douglas BrattonDirector
  • John CochranDirector
  • Santo CostaDirector
  • Peter BoydExecutive Officer
  • James S ScibettaDirector
  • Daniel BarberExecutive Officer
  • John T MaxwellExecutive Officer
Offering amount
$9.1M
Amount sold
$9.1M
Minimum investment
$100
First sale
Apr 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events
$367.5Mvaluation at IPOJul 2018 · $15.00/share · 424B4
filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Frequently asked questions

What does Aquestive Therapeutics do?
Aquestive Therapeutics develops and commercializes oral film drug formulations and other novel delivery systems for treatments in neurology, psychiatry, and emergency care, operating manufacturing facilities in Indiana that produce both licensed pharmaceutical products and proprietary candidates for regulated markets including the U.S., EU, and Australia.
Who are Aquestive Therapeutics's investors?
Aquestive Therapeutics's investors include Oaktree, RTW Investments L.P..
How much funding has Aquestive Therapeutics raised?
Aquestive Therapeutics has disclosed $9.1M raised across 1 round.
Where is Aquestive Therapeutics headquartered?
Aquestive Therapeutics is headquartered in Warren, US.